Alvotech's FDA Wins and Lotus Deal Offset Heavy Dilution
Dilution from $125M equity raise Alvotech sold new shares to raise about $125 million, which means each existing share now represents a smaller slice of the company. That dilutes current holders and is a direct drag on the stock price, even though the cash funds biosimilar development and launches.
This is the first major event of the period and a clear negative price driver.
$240M total capital raised, but costly debt Alvotech added a $75 million term loan to the $165 million equity raise, giving it $240 million in fresh capital for its pipeline and global expansion. The loan carries a high 12.5% interest rate, so it strengthens the balance sheet but adds real leverage risk that could weigh on future profits.
This is the period's key financing update and explains both the cash cushion and the added risk.
FDA clears Reykjavik plant, unlocking biosimilar approvals The FDA closed its inspection of Alvotech's Iceland factory with a clean 'Voluntary Action Indicated' status, meaning problems were fixed. This removes a regulatory cloud and supports pending U.S. applications for several biosimilars, making future approvals and sales more likely.
This is a new regulatory milestone that directly lifts the stock and de-risks the pipeline.
Lotus deal and AVT80 FDA acceptance expand market reach Alvotech signed a licensing deal with Lotus for two biosimilars worth up to $150 million plus supply revenue, and the FDA accepted its application for AVT80, a subcutaneous Entyvio biosimilar. Both broaden access to oncology, hematology and gut-disease markets, though near-term revenue still depends on approval timing.
These are the period's main growth catalysts, adding new revenue streams and pipeline progress.